SSY Group (02005.HK): Diltiazem Hydrochloride for Injection and Propranolol Hydrochloride Injection Obtain Drug Production Registration Approvals

NewTimeSpace News: SSY Group Limited (02005.HK) released a voluntary announcement on April 27, 2026. The Group has been granted the drug production registration approval by the NMPA for Diltiazem Hydrochloride for Injection (10mg). Falling into the category of Class 4 chemical drugs, the product is deemed to have completed the generic consistency evaluation. It is mainly indicated for supraventricular tachycardia, emergency management of intraoperative hypertension, hypertensive emergencies and unstable angina.

In addition, the Group obtained NMPA production registration approval for Propranolol Hydrochloride Injection (5ml:5mg & 2ml:2mg), a Class 3 chemical drug with deemed consistency evaluation clearance. This product is widely used to control supraventricular and ventricular arrhythmias, effort angina, and phaeochromocytoma (combined withα-blockers for tachycardia management.

Previously, the Group’s propranolol hydrochloride active pharmaceutical ingredient (API) has been officially registered and approved by the NMPA for use in marketed pharmaceutical preparations.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.